Microbiology
Microbiology is the study of microscopic organisms, such as bacteria, viruses, archaea, fungi, prions, algae and protozoa. These microbes play key roles in nutrient cycling, biodegradation/biodeterioration, climate change, food spoilage, the cause and control of disease, and biotechnology. Some of the most important discoveries that have underpinned modern society have resulted from the research of famous microbiologists. Microbiology research has been, and continues to be, central to meeting many of the current global aspirations and challenges.
This discipline includes fundamental research on the biochemistry, physiology, cell biology, ecology, evolution and clinical aspects of microorganisms, including the host response to these agents. Applications include biotechnology, agriculture, medicine, food microbiology and bioremediation.
- Cellular Microbiology
- Pharmaceutical Microbiology
- Virology
- Clinical Microbiology
- Food Microbiology
- Microbial Genetics
- Environmental Microbiology
- Phage Biology
- Microbial Energy
- Agriculture Microbiology
- Parasitology
- Microbial Communities
Trending News
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE